JPWO2023283613A5 - - Google Patents
Info
- Publication number
- JPWO2023283613A5 JPWO2023283613A5 JP2024500479A JP2024500479A JPWO2023283613A5 JP WO2023283613 A5 JPWO2023283613 A5 JP WO2023283613A5 JP 2024500479 A JP2024500479 A JP 2024500479A JP 2024500479 A JP2024500479 A JP 2024500479A JP WO2023283613 A5 JPWO2023283613 A5 JP WO2023283613A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- complex
- optionally
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163219999P | 2021-07-09 | 2021-07-09 | |
| US63/219,999 | 2021-07-09 | ||
| PCT/US2022/073527 WO2023283613A1 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024525611A JP2024525611A (ja) | 2024-07-12 |
| JPWO2023283613A5 true JPWO2023283613A5 (https=) | 2025-07-16 |
| JP2024525611A5 JP2024525611A5 (https=) | 2025-07-16 |
Family
ID=84802088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500479A Pending JP2024525611A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240318176A1 (https=) |
| EP (1) | EP4367147A4 (https=) |
| JP (1) | JP2024525611A (https=) |
| KR (1) | KR20240032945A (https=) |
| CN (1) | CN118355035A (https=) |
| AU (1) | AU2022307086A1 (https=) |
| CA (1) | CA3226365A1 (https=) |
| IL (1) | IL309937A (https=) |
| MX (1) | MX2024000494A (https=) |
| WO (1) | WO2023283613A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| EP3829595A4 (en) | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL309936A (en) | 2021-07-09 | 2024-03-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of dystrophinopathy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20250339553A1 (en) | 2022-04-15 | 2025-11-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008504222A (ja) * | 2003-12-15 | 2008-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 新規の抗ｄｃ−ｓｉｇｎ抗体 |
| PL2121751T3 (pl) * | 2006-12-08 | 2017-07-31 | Lexicon Pharmaceuticals, Inc. | Przeciwciała monoklonalne przeciwko ANGPTL3 |
| PE20141114A1 (es) * | 2010-12-20 | 2014-09-15 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| RU2014109038A (ru) * | 2011-08-23 | 2015-09-27 | Рош Гликарт Аг | Антитела к хондроитинсульфат протеогликану меланомы |
| CN117721110A (zh) * | 2011-12-28 | 2024-03-19 | 日本新药株式会社 | 反义核酸 |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| HRP20230528T1 (hr) * | 2016-03-22 | 2023-08-04 | F. Hoffmann - La Roche Ag | Bispecifične molekule t stanica aktivirane proteazom |
| US20200282074A1 (en) * | 2017-09-22 | 2020-09-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
| JP7576542B2 (ja) * | 2018-08-02 | 2024-10-31 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびそれらの使用 |
| EP3829595A4 (en) * | 2018-08-02 | 2022-08-24 | Dyne Therapeutics, Inc. | MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES |
| US12497615B2 (en) * | 2019-04-25 | 2025-12-16 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| WO2021142313A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| KR20230044242A (ko) * | 2020-07-23 | 2023-04-03 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
-
2022
- 2022-07-08 KR KR1020247004290A patent/KR20240032945A/ko active Pending
- 2022-07-08 US US18/577,374 patent/US20240318176A1/en active Pending
- 2022-07-08 JP JP2024500479A patent/JP2024525611A/ja active Pending
- 2022-07-08 CA CA3226365A patent/CA3226365A1/en active Pending
- 2022-07-08 IL IL309937A patent/IL309937A/en unknown
- 2022-07-08 CN CN202280059693.4A patent/CN118355035A/zh active Pending
- 2022-07-08 MX MX2024000494A patent/MX2024000494A/es unknown
- 2022-07-08 EP EP22838585.2A patent/EP4367147A4/en active Pending
- 2022-07-08 AU AU2022307086A patent/AU2022307086A1/en active Pending
- 2022-07-08 WO PCT/US2022/073527 patent/WO2023283613A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and their uses for the treatment of dystrophinopathy | |
| JPWO2023283624A5 (https=) | ||
| JPWO2023283615A5 (https=) | ||
| JPWO2023283613A5 (https=) | ||
| JPWO2023283619A5 (https=) | ||
| JPWO2023283614A5 (https=) | ||
| JPWO2021142307A5 (https=) | ||
| JPWO2022020107A5 (https=) | ||
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20240216522A1 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| CA3226301A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| IL315944A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL311507A (en) | Dosing of muscle targeting complexes for the treatment of dystrophinopathy | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| IL312170A (en) | Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JPWO2020028832A5 (https=) | ||
| JPWO2021142313A5 (https=) |